Drug data last refreshed 23h ago · AI intelligence enriched 1w ago
Trovan Preservative Free is an injectable fluoroquinolone antibiotic (alatrofloxacin mesylate) approved by Pfizer in 1997 for serious bacterial infections. It is a small-molecule IV formulation designed for hospitalized patients requiring parenteral antimicrobial therapy. The drug works by inhibiting bacterial DNA gyrase and topoisomerase IV, disrupting bacterial DNA replication.
This product is in late-stage lifecycle with approaching loss of exclusivity, signaling potential team consolidation and transition focus toward managed care and generic containment strategies.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on Trovan Preservative Free offers limited growth opportunity but provides valuable experience in mature product management, payer negotiations, and generic transition strategy. This role is best suited for professionals seeking expertise in end-of-life brand management or those transitioning into managed care and cost-containment specialties.
Worked on TROVAN PRESERVATIVE FREE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.